Market Live: Sensex extends gains, Nifty firmly above 9600; banks gain
Tue Jun 13 2017
Ramesh Sridharan (877 articles)

Market Live: Sensex extends gains, Nifty firmly above 9600; banks gain

12:11 pm Market Check: Equity benchmark indices traded steady after it extended its gains in the previous session, with the Nifty inching closer to 9650-mark.

The Sensex was up 98.03 points at 31193.73, while the Nifty was up 25.35 points at 9641.75. The market breadth was slightly narrow as 1,463 shares advanced, against a decline of 888 shares, while 161 shares were unchanged.

Midcaps continued to strengthen, while IT stocks cracked, with the IT index on the Nifty falling nearly a percent.

HDFC, Lupin, Bank of Baroda and Yes Bank were the top gainers, while Tata Motors, TCS, Tata Motors DVR and Tech Mahindra lost the most.

Also Read: Tejas Networks’ IPO opens on June 14; all you need to know about it

11:53 am USFDA audit: Jeevan Scientific Technology shares were locked at 5 percent upper circuit at Rs 39.80 on successful completion of first audit by the US health regulator.

The company said the US Food and Drug Administration conducted an un-announced audit of company’s corporate and clinical pharmacology centre facilities. The purpose of this audit was to review the BA/BE studies.

The USFDA started review of facilities on June 5 and completed on June 8, 2017.

“Auditors were pleased with procedures and processes which resulted with no 483 observations,” Jeevan Scientific said.

11:25 am Buzzing Stock: Investors cheered multiple developments around Jaiprakash Associates, which sent the stock soaring nearly 12 percent intraday on Tuesday.

According to reports on CNBC-TV18, the deal between the company and UltraTech Cement is likely to be closed by the end of this month. Approvals from Uttar Pradesh and Andhra Pradesh is already is in place, while a nod is awaited from Madhya Pradesh and Himachal Pradesh, the report added, quoting sources.

On the regulatory front, the company already has approvals from the National Company Law Tribunal, Competition Commission of India as well as from shareholders. The valuation of this deal is pegged at Rs 16,189 crore.

Also Read: India’s new-found fondness for fitness gives Cosco plenty of bounce

11:10 am Market Check: Benchmark indices extended their gains from the morning session, with the Nifty firmly above 9600- mark, which it had breached on Monday.

The Sensex was up 97.10 points at 31192.80, while the Nifty was up 22.60 points at 9639.00. The market breadth was health as 1,435 shares advanced against a decline of 785 shares, while 119 shares were unchanged.

Banks, both private and public, gained and helped the indices rise, while midcaps too gained. FMCG and metals witnessed marginal correction as well.

HDFC, Sun Pharma, Bank of Baroda and ACC gained the most, while Tata Motors, Infosys, Tech Mahindra and Vedanta lost the most.

Also Read: Revenue Secretary Hasmukh Adhia dismisses talk of GST rollout being delayed

11:00 am Buzzing Stock: Shares of Cadila Healthcare were higher by 1.5 percent intraday on Tuesday as investors cheered a recent product nod by US drug regulator.

The pharmaceutical major received a nod from the US Food and Drug Administration for Ezetimibe drug, which is used to treat high cholesterol. The news holds significance as the approval for the product from its Moraiya facility in Gujarat, which was until recently under pressure from the watchdog.

“The estimated sales for Ezetimibe tablets is USD 2.7 billion as per IMS MAT April 2017,” the company told the exchanges in a statement.

10:44 am IPO: The initial public offering (IPO) of leading securities depository Central Depository Services (CDSL) will open on June 19 and close on June 21.

The price band of the offer is fixed from Rs 145-149 and little over 3.5 crore shares will be offloaded by CDSL through the Offer for Sale (OFS) route and 7 lakh shares would be reserved for employees.

CDSL, promoted by BSE, had filed draft red herring prospectus (DRHP) with the Securities and Exchange Board of India in December 2016.

The company will only be listed on National Stock Exchange and not on BSE since the latter is the promoter of the depository firm.

10:25 am Market Outlook: Foreign institutional investors (FIIs) which have off-late turned net sellers in the month of June after pouring in close to Rs 10,000 crore in the month of May are very positive on Indian markets assures Pramod Gubbi, managing director and head equities, at Ambit Institutional Equities.

“FIIs continue to be positive in India given the nature of the economy is largely dependent on the domestic market as opposed to other emerging markets (EMs) which are dependent on the global economy,” said Gubbi.

He further said that I don’t think there is any left out feeling among FIIs poured in money in receding years which has made a lot of returns for the market. I don’t think last 8-month suggest they have had any serious issue abut India as an investible market.

10:00 am Market check: The broader markets outperformed benchmarks in morning trade, with the BSE Midcap and Smallcap indices rising more than half a percent.

The 30-share BSE Sensex gained 69.63 points at 31,165.33 and the 50-share NSE Nifty rose 17.65 points to 9,634.05.

The market breadth remained strong as about two shares advanced for every share falling on the BSE.

Sun Pharma was biggest gainer among Sensex stocks, up nearly 2 percent followed by ICICI Bank, HDFC, Maruti Suzuki, Lupin, L&T and HUL. TCS, Infosys, Tata Motors and ITC were under pressure.

9:41 am Buzzing: Shares of Sun Pharmaceutical Industries advanced as much as 3.4 percent in morning trade on the back of USFDA approval for generic Zetia tablets.

The company’s wholly owned subsidiaries has received final approval from United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Zetia, (ezetimibe) tablets 10mg.

The tablet Zetia is used to lower cholesterol in the blood. These generic ezetimibe tablets are therapeutic equivalents of Merck’s Zetia tablets.

According to IMS data, ezetimibe tablets had annual sales of approximately USD 2.7 billion in the US for the 12 months ended April 2017.

9:32 am Market Update: Benchmark indices gained strength after opening flat. The 30-share BSE Sensex was up 89.49 points at 31,185.19 and the 50-share NSE Nifty rose 24.90 points to 9,641.30, following upmove in Asia after mixed trade.

About three shares advanced for every share falling on the BSE.

Among Asian shares, Hong Kong’s Hang Seng, Australia’s ASX 200, South Korea’s Kospi and China’s Shanghai gained 0.4-1 percent.

9:25 am Market Outlook: Anish Damania of IDFC said the market will now closely monitor an expected short-term disruption from GST implementation and a still looming mild threat from El Nino.

He continues to maintain Nifty FY18 target at 9,825.

9:15 am Market Check: Equity benchmarks opened flat but the broader markets outperformed on Monday, after industrial output and retail inflation data.

The 30-share BSE Sensex was down 4.79 points at 31,090.91 and the 50-share NSE Nifty rose 2.15 points to 9,618.55. About three shares advanced for every share falling on the NSE.

Sugar stocks were in action as Ugar Sugar, Rana Sugar, Shree Renuka Sugars, Bajaj Hindusthan and Balrampur Chini gained 4-8 percent.

Among other midcaps, Ashok Leyland, Delta Corp, PFC, OBC and Syndicate Bank were up 1-2 percent while Bharat Financial was down nearly 1 percent. Vascon Engineers fell 10 percent.

The Indian rupee opened flat at 64.43 per dollar versus previous close 64.44.

Bhaskar Panda of HDFC Bank feels India story keeps the USD-INR rangebound. He expects a range of 64.35-64.55/dollar to play out for today.

India’s retail inflation rate fell to 2.18 percent in May, lowest since 2012, mainly due to a fall in food prices.
India’s factory output grew 3.1 percent in April from 2.7 percent in March, amid revival signs.

Ramesh Sridharan

Ramesh Sridharan

Ramesh Sridharan is our Stock Market Correspondent covering events and daily movements of stock markets in Asia. He is based in Mumbai

Discussion

Rules of Discussion on Live Index

1. This forum is for discussion of financial markets. Please respect others view even if they are contrary to you.
2. Member's comments should lead to value addition in forum discussion.
3. If anyone is found making repetitive Explicit/Abusive/Racial comments, his account shall be banned and old posts will be deleted.